Lung Cancer Test Kit

In 2020, lung cancer was the second most frequently diagnosed cancer and the leading cause of cancer-related mortality[1]. The majority of lung cancers (approximately 85 percent) are non-small cell lung cancer (NSCLC), with the remaining portion being predominantly small cell lung cancer (SCLC). The primary objective for each patient with suspected lung cancer is to obtain a timely diagnosis and precise staging to enable the administration of the most suitable therapy.input:
output:Blood-based biomarkers are indispensable diagnostic instruments for the treatment of lung cancer patients. They are utilized for the estimation of prognosis, stratification for specific therapies, monitoring of therapy response, surveillance monitoring, and early detection of residual or progressive disease, in addition to supporting differential diagnosis and histological subtyping. Twoinput:
output:CEA, CYFRA21-1, and NSE are tumor markers that are employed to monitor the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma, and small-cell lung cancer, respectively. ProGRP is a valuable marker in SCLC, as it has been shown to have an association with survival in NSCLC and SCLC (univariate analysis).Three SCCA has been verified to be closely associated with the prognosis of lung cancer, particularly squamous cell carcinoma[4].input:
output:Clinical Significanceinput:
output:
In stages IB NSCLC, the expression of tumor CEA may be elevated, which may serve as an adverse prognostic indicator. In clinical stage I NSCLC patients who were undergoing surgery, a high CEA level was a risk factor for occult regional node metastasis and a negative prognostic factor for survival, as indicated by retrospective studies.